SCHEMBL17397181

SCHEMBL17397181

CC(=O)c1cc2cccc(C)n2c(=O)c1Br

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.39
FNTA P49354 4/20 0.36
FNTB P49356 4/20 0.36
CCR1 P32246 1/20 0.34
BRD4 O60885 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
RXFP1 Q9HBX9 4/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 4/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
ALDH1A1 P00352 1/20 0.32
MAOA P21397 2/20 0.31
MAOB P27338 1/20 0.31
HPGD P15428 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17397208 0.74 MAPT (0.41) KDM4EBRD4L3MBTL1RXFP1MEN1
SCHEMBL17397300 0.71 PIK3CD (0.42) KDM4EFNTAFNTBALDH1A1HPGD
SCHEMBL17397156 0.70 KDM4E (0.35) KDM4EKMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL10361997 0.68 KDM4E (0.42) KDM4EFNTAFNTBHTTALDH1A1
SCHEMBL17397095 0.66 L3MBTL1 (0.34) BRD4L3MBTL1RXFP1ALDH1A1MAOA
SCHEMBL10361544 0.63 KDM4E (0.64) KDM4ERXFP1MEN1KMT2AALDH1A1
SCHEMBL697650 0.62 BRPF1 (0.46) KDM4EMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL3892014 0.60 KDM4E (0.39) KDM4EFNTAFNTBL3MBTL1MEN1
SCHEMBL1873518 0.59 KMT2A (0.41) KDM4EMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL1447795 0.58 ALDH1A1 (0.48) KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
EP-3164400-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS Lupin Limited (IN) 2017-05-10 EP disclosed
WO-2016001855-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2016-01-07 WO disclosed
WO-2016001855-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2016-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS PIK3R5, PIK3R1, PIK3R4 KDM4E 904/4885FNTA 2912/4885FNTB 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.